Webdisclosure.com

Search

UCB (EBR:UCB) UCB Media Room: UCB updates its financial outlook for 2019

Directive transparence : information réglementée

10/01/2020 18:10
https://mb.cision.com/Public/18595/3006365/8f39e7cbf3662ca0_800x800ar.jpg ** UCB updates its financial outlook for 2019 ------------------------------------------------------------ =C2=B7 Stronger than expected net sales lead to higher earnings level in 20= 19 =C2=B7 UCB=E2=80=99s Full Year 2019 results will be presented on 20 Februar= y 2020 Brussels, Belgium 10 January 2020, 18:00 CET, regulated information =E2=80= =93 inside information =E2=80=93 unaudited financials - UCB, a global bioph= armaceutical company, today announced an updated financial outlook for 2019: =C2=B7 Total revenue in 2019 are expected to reach approx. =E2=82=AC 4.9bn = =E2=80=93 previous outlook was in the range of =E2=82=AC 4.6 =E2=80=93 4.7b= n.=C2=A0 =C2=B7 The underlying profitability (recurring EBITDA) is now expected at l= east at the upper end of the range of 27% - 29% of revenue - previous guida= nce was in the range of 27% =E2=80=93 29%.=C2=A0 =C2=B7 Also the Core EPS are now expected to be higher than =E2=82=AC 4.80 = =E2=80=93 previous range was =E2=82=AC 4.40 =E2=80=93 4.80 These changes are driven by better than expected net sales, due to strong d= emand for Cimzia^=C2=AE and Vimpat^=C2=AE in the fourth quarter 2019. To op= timize the growth opportunity additional marketing activities were funded. The full financial statements for 2019 will be published on 20 February 202= 0.=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 7 500 people in= approximately 40 countries, UCB generated revenue of =E2=82=AC 4.6 billion= in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Tw= itter: @UCB_news For further information, UCB: Corporate Communications Laurent Schots=C2=A0 Media Relations, UCB =C2=A0 T+32.2.559.92.64 =C2=A0Laurent.schots@ucb.com=C2=A0 Investor Relations Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0 Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Isabelle Ghellynck, =C2=A0Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0 Forward looking statements UCB This press release contains forward-looking statements including, without l= imitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =E2= =80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=E2= =80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestimate= s=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccontinu= e=E2=80=9D and similar expressions. These forward-looking statements are ba= sed on current plans, estimates and beliefs of management. All statements, = other than statements of historical facts, are statements that could be dee= med forward-looking statements, including estimates of revenues, operating = margins, capital expenditures, cash, other financial information, expected = legal, arbitration, political, regulatory or clinical results or practices = and other such estimates and results. By their nature, such forward-looking= statements are not guarantees of future performance and are subject to kno= wn and unknown risks, uncertainties and assumptions which might cause the a= ctual results, financial condition, performance or achievements of UCB, or = industry results, to differ materially from those that may be expressed or = implied by such forward-looking statements contained in this press release.= Important factors that could result in such differences include: changes i= n general economic, business and competitive conditions, the inability to o= btain necessary regulatory approvals or to obtain them on acceptable terms = or within expected timing, costs associated with research and development, = changes in the prospects for products in the pipeline or under development = by UCB, effects of future judicial decisions or governmental investigations= , safety, quality, data integrity or manufacturing issues; potential or act= ual data security and data privacy breaches, or disruptions of our informat= ion technology systems, product liability claims, challenges to patent prot= ection for products or product candidates, competition from other products = including biosimilars, changes in laws or regulations, exchange rate fluctu= ations, changes or uncertainties in tax laws or the administration of such = laws, and hiring and retention of its employees. There is no guarantee that= new product candidates will be discovered or identified in the pipeline, o= r that new indications for existing products will be developed and approved= . Movement from concept to commercial product is uncertain; preclinical res= ults do not guarantee safety and efficacy of product candidates in humans. = So far, the complexity of the human body cannot be reproduced in computer m= odels, cell culture systems or animal models. The length of the timing to c= omplete clinical trials and to get regulatory approval for product marketin= g has varied in the past and UCB expects similar unpredictability going for= ward. Products or potential products which are the subject of partnerships,= joint ventures or licensing collaborations may be subject to disputes betw= een the partners or may prove to be not as safe, effective or commercially = successful as UCB may have believed at the start of such partnership. UCB= =E2=80=99 efforts to acquire other products or companies and to integrate t= he operations of such acquired companies may not be as successful as UCB ma= y have believed at the moment of acquisition. Also, UCB or others could dis= cover safety, side effects or manufacturing problems with its products and/= or devices after they are marketed. The discovery of significant problems w= ith a product similar to one of UCB=E2=80=99s products that implicate an en= tire class of products may have a material adverse effect on sales of the e= ntire class of affected products. Moreover, sales may be impacted by intern= ational and domestic trends toward managed care and health care cost contai= nment, including pricing pressure, political and public scrutiny, customer = and prescriber patterns or practices, and the reimbursement policies impose= d by third-party payers as well as legislation affecting biopharmaceutical = pricing and reimbursement activities and outcomes. Finally, a breakdown, cy= berattack or information security breach could compromise the confidentiali= ty, integrity and availability of UCB=E2=80=99s data and systems.=C2=A0 Given these uncertainties, you should not place undue reliance on any of su= ch forward-looking statements. There can be no guarantee that the investiga= tional or approved products described in this press release will be submitt= ed or approved for sale or for any additional indications or labelling in a= ny market, or at any particular time, nor can there be any guarantee that s= uch products will be or will continue to be commercially successful in the = future. UCB is providing this information, including forward-looking statements, on= ly as of the date of this press release and expressly disclaims any duty to= update any information contained in this press release, either to confirm = the actual results or to report or reflect any change in its forward-lookin= g statements with regard thereto or any change in events, conditions or cir= cumstances on which any such statement is based, unless such statement is r= equired pursuant to applicable laws and regulations.=C2=A0 Additionally, information contained in this document shall not constitute a= n offer to sell or the solicitation of an offer to buy any securities, nor = shall there be any offer, solicitation or sale of securities in any jurisdi= ction in which such offer, solicitation or sale would be unlawful prior to = the registration or qualification under the securities laws of such jurisdi= ction. GenericFile UCB updated outlook press release ENG (https://mb.cision.com/Public/18595/3= 006365/83ee552bedcf482e.pdf)=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x33214x1x6868579x24000= x6&Email=3Dregnews%40symexglobal.com.=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

24/02/2020 20:00
20/02/2020 07:00
14/02/2020 20:01
10/02/2020 20:00
31/01/2020 20:01
28/01/2020 07:01
27/01/2020 20:00
20/01/2020 20:10
20/01/2020 20:05
20/01/2020 20:01